Epizyme, Inc. (EPZM) financial statements (2020 and earlier)

Company profile

Business Address 400 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:381293331371240181216
Cash and cash equivalents1399346144876668
Short-term investments242199285227154115148
Other undisclosed cash, cash equivalents, and short-term investments000(0)(0)0(0)
Receivables31213132012 
Other undisclosed current assets1616141512721
Total current assets:399321358399273200236
Noncurrent Assets
Operating lease, right-of-use asset219  
Property, plant and equipment2222222
Other noncurrent assets2211111
Other undisclosed noncurrent assets  1011   
Total noncurrent assets:25131313333
TOTAL ASSETS:425334371413276203239
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities31252524242729
Accounts payable95785611
Accrued liabilities23191816202018
Deferred revenue 2  
Debt33  000
Contract with customer, liability6513  
Other liabilities0000000
Other undisclosed current liabilities  33   
Total current liabilities:34293432382729
Noncurrent Liabilities
Long-term debt and lease obligation197  000
Capital lease obligations000
Operating lease, liability197  
Liabilities, other than long-term debt4444555
Deferred revenue and credits4
Deferred revenue44  
Contract with customer, liability4444 
Other liabilities0000111
Total noncurrent liabilities:231144555
Total liabilities:57403836423134
Stockholders' equity
Stockholders' equity attributable to parent331294326368233172206
Preferred stock37373737   
Common stock0000000
Additional paid in capital1,051957953947820736732
Accumulated other comprehensive income (loss)0000(0)(0)(0)
Accumulated deficit(757)(701)(665)(616)(587)(564)(526)
Total stockholders' equity:331294326368233172206
Other undisclosed liabilities and equity36 89   
TOTAL LIABILITIES AND EQUITY:425334371413276203239

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:466810 12
Operating expenses(62)(44)(57)(39)(34)(39)(42)
Operating loss:(57)(38)(51)(31)(24)(39)(30)
Nonoperating income1222111
Loss from continuing operations before income taxes:(56)(36)(48)(29)(23)(37)(29)
Other undisclosed loss from continuing operations(0)   (0)  
Net loss attributable to parent:(56)(36)(48)(29)(23)(37)(29)
Other undisclosed net loss available to common stockholders, basic   (3)   
Net loss available to common stockholders, diluted:(56)(36)(48)(32)(23)(37)(29)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(56)(36)(48)(29)(23)(37)(29)
Comprehensive loss:(56)(36)(48)(29)(23)(37)(29)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)00(0)00
Comprehensive loss, net of tax, attributable to parent:(57)(36)(48)(29)(23)(37)(29)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: